Second-line therapy for advanced non-small-cell lung cancer

Current Oncology Reports

Volumn 8, Issue 4, 2006, Pages 243-247

  Hann, Christine L ^b   Brahmer, Julie R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CYANOCOBALAMIN; CYTOTOXIC AGENT; DOCETAXEL; ERLOTINIB; FOLIC ACID; FOLIC ACID ANTAGONIST; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; SUNITINIB; VANDETANIB;

ADVANCED CANCER; ALOPECIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG ERUPTION; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; HUMAN; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PAIN; PROTEINURIA; RECURRENT CANCER; SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; PROGNOSIS; SALVAGE THERAPY;

EID: 33745678478     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0027-3     Document Type: Article

References (38)

1. Cancer Facts & Figures 2005 Graphs and Figures. American Cancer Society. http://www.cancer.org/doc-root/STT/stt_0.asp
2. Spira A, Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 2004, 350:379-392.
3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. MMJ 1995, 311:899-909.
4. Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 1993, 11:1866-1872.
5. Souquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993, 342:19-21.
6. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
7. Sandler AB, Gray R, Brahmer J, et al.: Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 [abstract]. Proc ASCO 2005, 23:1090S. http://www.asco.org
8. Non-Small Cell Lung Cancer Version 2.2006. National Comprehensive Cancer Network Guidelines. http://www.nccn.org
9. Huisman C, Smit EF, Giaccone G, Postmus PE: Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 2000, 18:3722-3730.
10. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997, 15:2996-3018.
11. Fossella FV, Lee JS, Shin DM, et al.: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 1995, 13:645-651.
12. Burris HA, Eckardt J, Fields S, et al: Phase II trials of Taxotere in patients with non-small-cell lung cancer [abstract]. Proc ASCO 1993, 12:335a.
13. Shepherd FA, Dancey J, Ramlau R, et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
14. Fossella FV, DeVore R, Kerr RN, et al.: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000, 18:2354-2362.
15. Dancey J, Shepherd RA, Gralla RJ, Kim YS: Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004, 43:183-194.
16. Drugs FDA. U.S. Food and Drug Administration Center for Drug Evaluation and Research. http://www.accessdata.fda.gov/scripts/cder/drugsatfda
17. Baker SD, Zhao M, Lee CKKK, et al.: Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Can Res 2004, 10:1976-1983.
18. Camps C, Massuti B, Jiménez A, et al.: Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006, 17:467-472
19. Gridelli C, Gallo C, Di Maio M, et al.: A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004, 91:1996-2004.
20. Schuette W, Nagel S, Blankenburg T, et al.: Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005, 23:8389-8395.
21. Shih C, Chen VJ, Gossett LS, et al.: LY 231514, a pyrrolo [2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Can Res 1997, 57:1116-1123.
22. Clark SJ, Abratt R, Goadhals L, et al.: Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2002, 13:737-741.
23. Smit E, Mattson K, von Pawel J, et al.: ALIMTA (pemetrexed disodium) as second-line treatment of non-small cell lung cancer: a phase II study. Ann Oncol 2003, 14:455-460.
24. Rusthoven J, Eisenhauer E, Butts C, et al.: Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small cell lung cancer: A Phase II study - National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999, 17:1194-1199.
25. Hanna N, Shepherd FA, Fossella FV, et al.: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
26. Perez-Soler R, Chachoua A, Hammond LA, et al.: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:3238-3247.
27. Shepherd FA, Pereira JR, Ciuleanu T, et al.: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
28. Tsao MS, Sakurada A, Cutz JC, et al.: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
29. Herbst RS, Johnson DH, Mininberg E, et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:2544-2555.
30. Wedge SR, Ogilvie DJ, Dukes M, et al.: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis and tumor growth following oral administration. Can Res 2002, 62:4645-4655.
31. Ciardiello F, Caputo R, Damiano V, et al.: Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Can Res 2003, 9:1546-1556.
32. Heymach JV. ZD6474: clinical experience to date. Br J Cancer 2005, 92:S14-S20.
33. Minami H, Ebi H, Tahara M et al.: A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors [abstract]. Proc ASCO 2003, 22:194. http://www.asco.org
34. Heymach JV, Johnson BE, Rowbottom JA, et al.: A randomized placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC [abstract]. Proc ASCO 2005, 23:3023. http://www.asco.org
35. Herbst RS, Johnson B, Rowbottom JA, et al.: ZD6474 plus docetaxel in patients with previously treated NSCLC: results of a randomized, placebo controlled phase II trial [abstract]. Lung Cancer 2005, 49 (Suppl 2):S35 (abstract 0-100).
36. Mendel DB, Laird AD, Xin X, et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Can Res 2003, 9:327-337.
37. Faivre S, Delbado C, Vera K, et al.: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006:24:25-35.
38. Rosen L, Mulay M, Long J, et al.: Phase I trial of SU011248, a novel tyrosine kinase [abstract]. Proc ASCO 2003, 22:191. http://www.asco.org